Evaluation of11C-GSK189254 as a novel radioligand for the H 3 receptor in humans using PET

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1021-1029

  Ashworth, Sharon ^a   Rabiner, Eugenii A ^a   Gunn, Roger N ^a   Plisson, Christophe ^a   Wilson, Alan A ^b   Comley, Robert A ^a   Lai, Robert Y K ^c   Gee, Antony D ^a   Laruelle, Marc ^c   Cunningham, Vincent J ^a,d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Neurosciences CEDD   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Brain; GSK189254; H3 receptor; Human; Neurology; PET; Radiopharmaceuticals

Indexed keywords

6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE C 11; GSK 185071 B; HISTAMINE H3 RECEPTOR; METHYL IODIDE C 11; RADIOISOTOPE; RADIOLIGAND; UNCLASSIFIED DRUG; 6 ((3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YL)OXY) N METHYL 3 PYRIDINECARBOXAMIDE; 6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPIN-7-YL)OXY)-N-METHYL-3-PYRIDINECARBOXAMIDE; BENZAZEPINE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; NICOTINAMIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; DISSOCIATION CONSTANT; DRUG DISTRIBUTION; DRUG DOSE; FEMALE; HUMAN; IN VIVO STUDY; MALE; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; ALGORITHM; BIOTRANSFORMATION; DOSE RESPONSE; DRUG EFFECT; EVALUATION; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; STATISTICAL MODEL; SYNTHESIS;

ADULT; AGED; ALGORITHMS; BENZAZEPINES; BIOTRANSFORMATION; BRAIN; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NIACINAMIDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, HISTAMINE H3; REPRODUCIBILITY OF RESULTS;

EID: 77954964773     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.071753     Document Type: Article

References (32)

1. Watanabe T, Taguchi Y, Shiosaka S, et al. Distribution of the histaminergic neuron system in the central nervous system of rats: a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. Brain Res. 1984;295:13-25.
2. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol. 2001;63:637-672.
3. 3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol. 2007;73:1157-1171.
4. Hill SJ, Ganellin CR, Timmerman H, et al. International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev. 1997;49:253-278.
5. Nguyen T, Shapiro DA, George SR, et al. Discovery of a novel member of the histamine receptor family. Mol Pharmacol. 2001;59:427-433. (Pubitemid 32179919)
6. 3) visualised in the brain of human and nonhuman primates. Brain Res. 1990;526:322-327.
7. 3) of histamine receptor. Nature. 1983;302:832-837.
8. 3-receptor activation inhibits dopamine synthesis in rat striatum. Neuroreport. 2000;11:163-166.
9. 3 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999;360:558-564.
10. 3 receptor ligands and neurological disease. Expert Opin Investig Drugs. 2004;13:1237-1248.
11. 3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci USA. 2006;103:13866-13871.
12. 3 receptor antagonists reach out for the clinic. Drug Discov Today. 2005;10:1613-1627.
13. 3-receptors. Nature. 1987;327:117-123.
14. 3 receptors. J Pharmacol Exp Ther. 1994;271:452-459.
15. 3 receptor. J Labelled Comp Radiopharm. 1997;39:601-606. (Pubitemid 127082322)
16. 3 receptors. J Labelled Comp Radiopharm. 2000;43:873-882.
17. 3 receptor. Bioorg Med Chem. 1999;7:1761-1767.
18. 3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse. 2009;63:1122-1132.
19. 3 receptors by PET. J Nucl Med. 2009;50:2064-2072.
20. 3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007;321:1032-1045.
21. 3]-carbomethoxy-3B-aryltropanes: radiotracers for the dopamine transporter. J Labelled Comp Radiopharm. 1994;34:759-766.
22. 11C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol. 2000;27:529-532.
23. Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Ingelese E. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 Standard. J Nucl Med. 2005;46:2083-2091.
24. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Columnswitching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627-630.
25. Hammers A, Koepp MJ, Free S, et al. Implementation and application of a new brain template for multiple volumes of interest. Hum Brain Mapp. 2002;15:165-174.
26. Wellcome Trust Centre for Neuroimaging. Statistical Parametric Mapping. Available at: http://www.fil.ion. ucl.ac.uk/spm. Accessed May 6, 2010.
27. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
28. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46-50.
29. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635-652.
30. Chu M, Huang ZL, Qu WM, Eguchi N, Yao MH, Urade Y. Extracellular histamine level in the frontal cortex is positively correlated with the amount of wakefulness in rats. Neurosci Res. 2004;49:417-420.
31. 150 autoradiographic method and dynamic PET. J Nucl Med. 1989;30:1069-1078.
32. 2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach. J Cereb Blood Flow Metab. 1999;19:533-546.